Predictive Oncology Inc (POAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Predictive Oncology Inc (POAI) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($-77.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See POAI defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Predictive Oncology Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Predictive Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Predictive Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Predictive Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Energy Focu
NASDAQ:EFOI
|
0.017x |
|
Harte Hanks Inc
NASDAQ:HHS
|
0.036x |
|
High-Tech Metals Ltd
AU:HTM
|
-0.072x |
|
Almadex Minerals Ltd
V:DEX
|
-0.024x |
|
Superhouse Limited
NSE:SUPERHOUSE
|
0.110x |
|
Prostar Holdings Inc
V:MAPS
|
-0.535x |
|
EAT WELL INVESTMENT GROUP
F:6BC0
|
N/A |
|
SAGTEC GLOBAL LIMITED Ordinary shares
NASDAQ:SAGT
|
0.281x |
Annual Cash Flow Conversion Efficiency for Predictive Oncology Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Predictive Oncology Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see POAI stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-202.61K | $-11.96 Million | 59.008x | +3800.73% |
| 2023-12-31 | $8.27 Million | $-13.19 Million | -1.595x | -180.55% |
| 2022-12-31 | $21.77 Million | $-12.37 Million | -0.568x | -87.45% |
| 2021-12-31 | $40.27 Million | $-12.21 Million | -0.303x | +93.46% |
| 2020-12-31 | $2.64 Million | $-12.26 Million | -4.638x | -496.57% |
| 2019-12-31 | $11.23 Million | $-8.73 Million | -0.778x | +99.21% |
| 2018-12-31 | $53.47K | $-5.29 Million | -98.890x | -5869.03% |
| 2017-12-31 | $2.69 Million | $-4.46 Million | -1.657x | +65.07% |
| 2016-12-31 | $923.68K | $-4.38 Million | -4.743x | -160.55% |
| 2015-12-31 | $4.11 Million | $-7.49 Million | -1.821x | -397.87% |
| 2014-12-31 | $-5.52 Million | $-3.37 Million | 0.611x | -48.98% |
| 2013-12-31 | $-3.22 Million | $-3.86 Million | 1.198x | +234.13% |
| 2012-12-31 | $-3.30 Million | $-1.18 Million | 0.358x | -45.61% |
| 2011-12-31 | $-2.70 Million | $-1.78 Million | 0.659x | +75.84% |
| 2010-12-31 | $-2.19 Million | $-820.68K | 0.375x | -32.99% |
| 2009-12-31 | $-2.34 Million | $-1.31 Million | 0.559x | -80.78% |
| 2008-12-31 | $-309.44K | $-900.53K | 2.910x | -- |
About Predictive Oncology Inc
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D cult… Read more